IDEXX jumps 3% as Citigroup shifts stance and sets $650 target
IDEXX Laboratories shares rose about 3.45% to roughly $589.39 as investors reacted to a fresh analyst rating change and a new $650 price target from Citigroup. The move builds on confidence in IDEXX’s 2026 outlook, which calls for $14.29–$14.80 in EPS.
1. What’s moving the stock today
IDEXX Laboratories (IDXX) is outperforming after a high-profile analyst call refreshed investor focus on valuation and the company’s medium-term earnings power. Citigroup issued a new rating action and published a $650 price target, helping lift sentiment and pushing shares higher in today’s session. (marketbeat.com)
2. Why the call matters
On a quiet news day for the company, incremental changes in Street stance can drive short-term price action—especially in large-cap healthcare names where institutional positioning is sensitive to target revisions. The $650 target provides a visible reference point for investors recalibrating upside/downside after IDEXX’s recent run and ahead of the next major fundamental update. (hosting.briefing.com)
3. Fundamental backdrop investors are watching
IDEXX has already laid out its initial 2026 framework, including EPS guidance of $14.29–$14.80 and revenue growth expectations supported by recurring companion animal diagnostics demand. Today’s strength suggests the market is leaning toward the view that IDEXX can execute into that outlook despite a mixed macro backdrop for discretionary spending and clinic traffic. (ir.idexx.com)
4. What to watch next
Traders will be watching for follow-through in analyst revisions, any additional target moves from peers, and management’s next update that could validate (or challenge) the current 2026 trajectory. Near-term upside durability will likely depend on whether incoming operating metrics and veterinary visit trends continue to support IDEXX’s premium growth profile. (ir.idexx.com)